Galcanezumab effect on “whole pain burden” and multidimensional outcomes in migraine patients with previous unsuccessful treatments: a real-world experience

Peer Review reports

Original Submission
17 Feb 2022	Submitted	Original manuscript
4 Mar 2022	Reviewed	Reviewer Report
21 Mar 2022	Reviewed	Reviewer Report
21 Apr 2022	Author responded	Author comments - Antonio Russo
Resubmission - Version 2
21 Apr 2022	Submitted	Manuscript version 2
Publishing
22 Apr 2022	Editorially accepted
13 Jun 2022	Article published	10.1186/s10194-022-01436-6

Back to article page